. Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. Am J Physiol Cell Physiol 291: C40 -C49, 2006. First published February 8, 2006 doi:10.1152/ajpcell.00351.2005.-Matriptase and its cognate inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1), have been implicated in carcinoma onset and malignant progression. However, the pathological mechanisms of matriptase activation are not defined. Steroid sex hormones play crucial roles in prostate and breast cancer. Therefore, we investigated the questions of whether and how steroid sex hormones regulate matriptase activation in these cancer cells. Treatment of cells with 17-estradiol had no effect on activation of matriptase in hormonestarved breast cancer cells, in part due to their high constitutive level of activated matriptase. In striking contrast, very low levels of activated matriptase were detected in hormone-starved lymph node prostatic adenocarcinoma (LNCaP) cells. Robust activation of matriptase was observed as early as 6 h after exposure of these cells to 5␣-dihydrotestosterone (DHT). Activation of matriptase was closely followed by shedding of the activated matriptase with Ͼ90% of total activated matriptase present in the culture media 24 h after DHT treatment. Activated matriptase was shed in a complex with HAI-1 and may result from simultaneously proteolytic cleavages of both membrane-bound proteins. Latent matriptase and free HAI-1 were also shed into culture media. As a result of shedding, the cellular levels of matriptase and HAI-1 were significantly reduced 24 h after exposure to DHT. DHT-induced matriptase activation and shedding were significantly inhibited by the androgen antagonist bicalutamide, by the RNA transcription inhibitor actinomycin D, and by the protein synthesis inhibitor cycloheximide. These results suggest that in LNCaP cells, androgen induces matriptase activation via the androgen receptor, and requires transcription and protein synthesis.androgen; hepatocyte growth factor activator inhibitor-1 MATRIPTASE and its inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1), represent a cognate pair, a cell surface proteolytic enzyme and its inhibitor (29). Both are broadly coexpressed by epithelial elements in most epithelium-containing tissues (18, 45). Matriptase, a type 2 transmembrane serine protease (40, 54), contains a COOH-terminal serine protease domain and several noncatalytic domains, including a sperm protein-enterokinase-agrin module, two tandem C1r/s-UegfBone morphogenic protein-1 domains, and four tandem lowdensity lipoprotein (LDL) receptor class A domains (19,30,57,59). Matriptase was shown to play an important role in epidermal barrier function, terminal epidermal differentiation, hair follicle development and thymic homeostasis in matriptase knockout mice (32). Some of these functions may result from its role in the maturation of pro-filaggrin (34), a marker for the terminal differentiation of keratinoc...